

### **REMARKS**

This response to restriction requirement is made to comply with the Office Action mailed May 21, 2008, having a one (1) month shortened statutory period for reply.

As the due date fell on a Saturday, June 21, 2008, in accordance with 37 C.F.R. § 1.7 (Times for Taking Action; Expiration on Saturday, Sunday or Federal Holiday), applicants submit this response on the succeeding business day, Monday, June 23, 2008.

Claims 1-19 and 27-34 are pending and subject to restriction in the above-identified application.

Applicants request consideration and entry into the record of the following amendments and remarks.


#### **Restriction Requirement**

In the May 21, 2008 Office Action, the Examiner has required restriction of claims 1-19 and 27-34 of the present invention to one of four groups, identified as Groups I to IV (identified below), and a respective selection of a corresponding species election:

- Group I: Claims 1-19 and 29-31, drawn to a compound of Formula (I) (see claim 1), or a pharmaceutical composition comprising a compound of Formula (I);
- Group II: Claim 27, drawn to a method of treatment of a human or animal subject having a condition where under-activation of the HM74A receptor contributes to the condition or where activation of the receptor will be beneficial, which method comprises administering an effective amount of a compound of Formula (I);
- Group III: Claims 28 and 34, drawn to a method of treatment of a human or animal subject having a disorder of lipid metabolism, which comprises administering an effective amount of a compound of Formula (I); and
- Group IV: Claims 32-33, drawn to a process for the preparation of a compound of Formula (I).

In response to the restriction requirement, applicants provisionally elect, without traverse, to prosecute:

- [1] Group I: Claims 1-19 and 29-31, drawn to a compound of Formula (I) (see claim 1), or a pharmaceutical composition comprising a compound of Formula (I); and
- [2] the species identified as Example 10 identified in Table on page 25:



U.S. Pat. Appln. Serial No.: 10/568,029  
Group Art Unit No.: 1611

### **CONCLUSION**

In view of the above amendments and remarks, applicants believe that the claims of the present application are in condition for allowance, which is earnestly solicited.

If any additional fees or charges are required authorization is hereby granted to charge any necessary fees to Deposit Account No. 19-2570 accordingly.

Should the Examiner have any questions or wish to discuss any aspect of this case, the Examiner is encouraged to call the undersigned attorney at the number below.

Respectfully submitted,



---

Grace C. Hsu  
Attorney for Applicants  
Registration No. 51,336

GLAXOSMITHKLINE  
Corporate Intellectual Property-UW2220  
P.O. Box 1539  
King of Prussia, PA 19406-0939  
Phone: (610) 270-4650  
Fax: (610) 270-5090  
*n:\gch\PB60300 office action.doc*